title: Mobilization of hemopoietic stem cells with high-dose methotrexate plus granulocyte-colony-stimulating factor in patients with primary central nervous system lymphoma.
abstract: BACKGROUND
  High-dose therapy with autologous stem cell support after standard dose induction is a promising approach for therapy of primary central nervous system lymphoma (PCNSL). High-dose methotrexate (HD-MTX) is a standard drug for induction of PCNSL; however, data about the capacity of HD-MTX plus granulocyte-colony-stimulating factor (G-CSF) to mobilize hemopoietic progenitors are lacking.
  
  
  METHODS
  This investigation describes the data from stem cell mobilization and apheresis procedures after one or two cycles of HD-MTX for induction of PCNSL within the East German Study Group for Haematology and Oncology 053 trial. Eligible patients proceeded to high-dose busulfan/thiotepa after induction therapy and mobilization.
  
  
  RESULTS
  Data were available from nine patients with a median age of 58 years. The maximal CD34+ cell count per microL of blood after the first course of HD-MTX was 13.89 (median). Determination was repeated in six patients after the second course with a significantly higher median CD34+ cell count of 33.69 per microL. Five patients required two apheresis procedures and in four patients a single procedure was sufficient. The total yield of CD34+ cells per kg of body weight harvested by one or two leukapheresis procedures was 6.60 x 10(6) (median; range, 2.68 x 10(6)-15.80 x 10(6)). The yield of CD34+ cells exceeded the commonly accepted lower threshold of 3 x 10(6) cells per kg of body weight in eight of nine cases. Even in the ninth, hemopoietic recovery after stem cell reinfusion was rapid and safe.
  
  
  CONCLUSIONS
  HD-MTX plus G-CSF is a powerful combination for stem cell mobilization in patients with PCNSL and permits safe conduction of time-condensed and dose-intense protocols with high-dose therapy followed by stem cell reinfusion after HD-MTX induction.
authors.affiliation: Department of Internal Medicine, Ernst-Moritz-Arndt-University, Greifswald, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Kiefer
authors.forename: William H
authors.initials: WH
authors.lastname: Krüger
authors.forename: Michael
authors.initials: M
authors.lastname: Montemurro
authors.forename: Frank
authors.initials: F
authors.lastname: Schüler
authors.forename: Carsten
authors.initials: C
authors.lastname: Hirt
authors.forename: Rita
authors.initials: R
authors.lastname: Pasold
authors.forename: Dietger
authors.initials: D
authors.lastname: Niederwieser
authors.forename: Matthias
authors.initials: M
authors.lastname: Schwenke
authors.forename: Gottfried
authors.initials: G
authors.lastname: Dölken
mesh_terms: D000328:Adult; D000368:Aged; D016543:Central Nervous System Neoplasms / Q000628:therapy*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000494:pharmacology*; D008875:Middle Aged
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D008727:Methotrexate